MedTrace Logo

Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction

NCT01042782 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2012-08-03

No results posted yet for this study

Summary

Patients with advanced gastric cancer are treated with a combination of RAD001 (everolimus) and Mitomycin C.

Conditions

  • Advanced Gastric Cancer
  • Advanced Cancer of the Esophagogastric Junction

Interventions

DRUG

RAD001 and MitomycinC

RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts) Mitomycin C 5 mg/m2 i.v. every 3 weeks

Sponsors & Collaborators

  • Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Salah-Eddin Al-Batran, MD · Krankenhaus Nordwest

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01042782 on ClinicalTrials.gov